Loading company…
Novelty Nobility develops therapeutic antibodies, antibody-drug conjugates, and related linker technologies.
Founded in 2017 and based in Seongnam, South Korea, Novelty Nobility develops antibody therapies and antibody-drug conjugates for cancer and other conditions. Its pipeline includes candidates for retinal disease, chronic urticaria, and cancer, alongside PREXISE-D antibody discovery and PREXISETM-L linker platforms. In May 2022, it raised KRW 34.1 billion in Series B funding from Albatross Investment, KB Investment, KB Securities, NH Investment & Securities, Samho Green Investment, SL investment, and others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in